Product Description
Rimexolone is as effective as prednisolone acetate ophthalmic suspension in the treatment of anterior uveitis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15847313/)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Brazil | Canada | Chile | Colombia | Egypt | Germany | Ireland | Italy | Mexico | Morocco | New Zealand | Peru | Portugal | Sweden | Taiwan | Turkey | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|